Combination therapy targeting angiogenesis using VEGF and angiopoietin-2 inhibitors combined with anti-PD-1 antibody inhibited Treg and MDSC infiltration and increased proliferation and anti-tumor activity of glioma-infiltrating CD8 T cells [90]. Here, PDCD1 is linked to neoplasm.